https://medicaldialogues.in/news/industry/pharma/usfda-nod-to-voydeya-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-extravascular-haemolysis-in-adults-with-rare-disease-pnh-astrazeneca-126583